key: cord-1016425-9tjd7dnp authors: Chirathaworn, Chintana; Sripramote, Manit; Chalongviriyalert, Piti; Jirajariyavej, Supunee; Kiatpanabhikul, Phatharaporn; Saiyarin, Jatuporn; Soudon, Chulikorn; Thienfaidee, Orawan; Na Ayuthaya, Thitisan Palakawong; Brukesawan, Chantapat; Chaiwanichsiri, Dootchai; Intharasongkroh, Duangnapa; Wanlapakorn, Nasamon; Chansaenroj, Jira; Puenpa, Jiratchaya; Yorsaeng, Ritthideach; Thitithanyanont, Arunee; Kitphati, Rungrueng; Mungaomklang, Anek; Nagavajara, Pijaya; Poovorawan, Yong title: SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts date: 2020-07-17 journal: bioRxiv DOI: 10.1101/2020.07.17.208439 sha: d9923c192744cd12b202d7c1760cd5391e287e41 doc_id: 1016425 cord_uid: 9tjd7dnp Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 emerged in December 2019 and has spread globally. Although Thailand has been effective at controlling the spread of COVID-19, disease surveillance and information on antibody responses in infected cases and close contacts are needed because there is still no specific treatment or vaccine available. We investigated 217 recovered COVID-19 cases to monitor their viral RNA shedding and production of antibodies against SARS-CoV-2. The presence of antibodies in blood samples from 308 close contacts of COVID-19 cases was also determined. Viral RNA was still detectable in 6.6 % of recovered COVID-19 cases. The most prolonged duration of viral RNA shedding detected in this study was 105 days. IgM, IgG, and IgA antibodies against SARS-CoV-2 were detected in 13.82, 88.48, and 83.41 % of the recovered cases 4–12 weeks after disease onset, respectively. Although the patients had recovered from their illness, the levels of antibodies detected showed association with their symptoms during their stay in hospital. Fifteen of the 308 contacts (4.87 %) of COVID-19 cases tested positive for IgG antibodies. The presence of antibodies against SARS-CoV-2 suggested that there was viral exposure among close contacts. Viral clearance and the pattern of antibody responses in infected individuals are both crucial for effectively combatting SARS-CoV-2. Our study provides additional information on the natural history of this newly emerging disease related to both natural host defenses and a strategy for vaccine development. In this study, we followed recovered COVID-19 cases using real-time RT-PCR to 100 investigate the duration of viral shedding as detected in NP swabs. Antibody detection was 101 performed to monitor antibody levels in all the recovered patients. Blood samples from 102 individuals who had a history of contact with COVID-19 patients were also collected for 103 antibody detection. The study protocol was approved by the Institutional Ethics Committee (IRB) of the respectively. Close contacts were individuals with a history of contact with COVID-19 patients. Only blood samples for antibody detection were collected from close contacts. For recovered cases, the duration between the first day of symptom onset to the day of 120 sample collection was recorded. For close contacts, the duration between the last contact and 121 sample collection was noted. (p = 0.001, p < 0.0001, and p < 0.0001, respectively) (Fig 2A-C) . and IgG were still detectable in more than 80 % of recovered cases. It would be interesting to 294 investigate further the recovered cases whose antibodies against SARS-CoV-2 were 295 undetectable. 296 We also found that high levels of antibodies were associated with disease severity. Interestingly, although we investigated the antibody levels in the recovered cases, an association 298 between high antibody levels and severe cases was still observed. This suggests that patients In this study, we investigated a large group of close contacts, and found that 4.8 % of 305 them displayed evidence of viral exposure. Besides, our results showed that household contact 306 represent a high-risk group for disease exposure which is essential for the prevention of disease 307 transmission. In conclusion, our study provided information on COVID-19 cases after disease 309 recovery. The data suggested that further monitoring should be performed to achieve a full Situation Report-167. Available at 329 hwwidd-scs-r-c--s-ps Department of Disease Control MoPH, Thailand. Covid-19 Situation Reports CoV-2 and the Ongoing Clinical Trials Coronaviridae Study Group of the International Committee on Taxonomy of V. The 336 species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV 337 and naming it SARS-CoV-2 COVID-19, SARS and 340 MERS: are they closely related? Cell entry mechanisms of 343 SARS-CoV-2 Nowcasting and forecasting the potential domestic and 346 international spread of the 2019-nCoV outbreak originating in Wuhan, China: a 347 modelling study The Incubation 350 Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed 351 Cases: Estimation and Application Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2 Serological immunochromatographic 358 approach in diagnosis with SARS-CoV-2 infected COVID-19 patients Development and clinical application of a 361 rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis Factors associated with duration of 364 viral shedding in adults with COVID-19 outside of Wuhan, China: A retrospective cohort 365 study Risk Factors for Viral RNA Shedding in 367 COVID-19 Patients CoV-2 viral shedding during COVID-19 infection Clinical course and risk factors for 373 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort 374 study Prolonged virus 377 shedding even after seroconversion in a patient with COVID-19 Viral dynamics in mild and 380 severe cases of COVID-19 A case of COVID-19 and 383 pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG 384 dynamic Dynamic Characteristics in Patients with COVID-19 Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in 391 Coronavirus Disease 2019 Patients. Emerging Infectious Disease journal Responses 1 Year after Symptom Onset, South Korea Antibody 397 Response and Disease Severity in Healthcare Worker MERS Survivors Chronological evolution of IgM IgG and neutralisation antibodies after infection with SARS-associated coronavirus Serological 404 and molecular findings during SARS-CoV-2 infection: the first case study in Finland Antibody responses to 408 SARS-CoV-2 in patients with COVID-19 Different longitudinal patterns 411 of nucleic acid and serology testing results based on disease severity of COVID-19 412 patients CoV-2 in patients of novel coronavirus disease 2019 Epidemiology and transmission of 418 COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a 419 retrospective cohort study Profiling Early Humoral Response 422 to Diagnose Novel Coronavirus Disease (COVID-19)